Urology Medical News about molecular pathology of low-risk prostate cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

What is the molecular pathology of low-risk prostate cancer
World Journal of Urology, 05/13/08

Samaratunga H et al. - FISH analysis or RT-PCR based assays to detect TMPRSS2: ETS fusion and immunohistochemical assessment of p27, EZH2 and c-MYC may become useful ancillary tests in patients with low risk prostate cancer. Some serum biomarkers have promise for future use. Large prospective studies followed by clinical trials are necessary before these molecular markers could be integrated into clinical practice.

<< Previous
Dietary fat intake and risk of prostate cancer in the European...

Next >>
Clinical and radiological characteristics of Nigerian boys with...

The value of EZH2, p27kip1, BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy
BJU International, 11/17/09 Relevance Score: 90%%

New cancer target for non-Hodgkins lymphoma
EurekAlert, 11/23/09 Relevance Score: 89%%

Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth
British Journal of Cancer, 11/06/09 Relevance Score: 89%%

Alternatively spliced tissue factor identified as promising new biomarker for aggressive cancers
EurekAlert, 10/27/09 Relevance Score: 89%%

Novel Lipogenic Enzyme ELOVL7 Is Involved in Prostate Cancer Growth through Saturated Long-Chain Fatty Acid Metabolism
Cancer Research, 10/21/09 Relevance Score: 89%%